Literature DB >> 8798874

Molecular modeling study of structural requirements for the oligopeptide transporter.

J Li1, I J Hidalgo.   

Abstract

The intestinal oligopeptide transporter (OPT) mediates the absorption of di-/tripeptides, beta-lactam antibiotics, angiotensin converting enzyme (ACE) inhibitors and renin inhibitors. This suggests that the targeting of molecules to this transporter could result in orally-absorbed drugs. Results from a recent study with renal brush border membrane vesicles (BBMV) suggested that an alpha-NH2 group is required for interaction with the renal OPT. In general, structural requirements for interaction with the renal and intestinal OPT are similar. However, these recent findings do not agree with earlier studies, which showed that an alpha-NH2 group is not essential for interaction with the intestinal OPT. Thus, it appears that the renal and intestinal OPT may differ in their recognition of compounds containing an alpha-NH2 group. In this study, molecular modeling was used to determine the tridimensional structures of various cephalosporins for which Ki values had been determined using renal BBMV. All cephalosporins which interact with the OPT have two, energetically equivalent, conformations. Most compounds which do not interact with the OPT cannot adopt the two conformations. A key factor which influences the conformation seems to be the substituent group at the alpha position; an electron drawing group at that position alters the common conformations. For the OPT substrates, the distances between the -NH2 and -COOH groups are comparable to those of the tripeptide, GlyGlyGly; and the distances between -NH2 and carbonyl group in the beta-lactam ring are close to the distance between N-terminal and C-terminal in the dipeptide, GlyGly. The corresponding distances in cephamycin C (in which a -NH2 group is located in a different position) and the tetrapeptide, GlyGlyGlyGly, are longer than those in alpha-NH2 cephalosporins and GlyGlyGly. Cephamycin C and the tetrapeptide have low affinity for the renal OPT, suggesting that the distances between functional groups are critical for affinity. The alpha-NH2 group had no effect on the conformations of the molecules. We concluded that the alpha-NH2 group may interact directly with the renal oligopeptide transporter. Whether this is unique to the renal transporter or could be applied to the intestinal transporter will require further investigation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8798874     DOI: 10.3109/10611869609046256

Source DB:  PubMed          Journal:  J Drug Target        ISSN: 1026-7158            Impact factor:   5.121


  8 in total

1.  Improvement of the intestinal absorption of a peptidomimetic, boronic acid thrombin inhibitor possibly utilizing the oligopeptide transporter.

Authors:  H Saitoh; B J Aungst
Journal:  Pharm Res       Date:  1999-11       Impact factor: 4.200

2.  Structure-activity relationship of carbacephalosporins and cephalosporins: antibacterial activity and interaction with the intestinal proton-dependent dipeptide transport carrier of Caco-2 cells.

Authors:  N J Snyder; L B Tabas; D M Berry; D C Duckworth; D O Spry; A H Dantzig
Journal:  Antimicrob Agents Chemother       Date:  1997-08       Impact factor: 5.191

3.  Intestinal transport of beta-lactam antibiotics: analysis of the affinity at the H+/peptide symporter (PEPT1), the uptake into Caco-2 cell monolayers and the transepithelial flux.

Authors:  B Bretschneider; M Brandsch; R Neubert
Journal:  Pharm Res       Date:  1999-01       Impact factor: 4.200

4.  Evidence for overlapping substrate specificity between large neutral amino acid (LNAA) and dipeptide (hPEPT1) transporters for PD 158473, an NMDA antagonist.

Authors:  N Surendran; K M Covitz; H Han; W Sadee; D M Oh; G L Amidon; R M Williamson; C F Bigge; B H Stewart
Journal:  Pharm Res       Date:  1999-03       Impact factor: 4.200

5.  In vitro and pharmacophore-based discovery of novel hPEPT1 inhibitors.

Authors:  Sean Ekins; Jeffrey S Johnston; Praveen Bahadduri; Vanessa M D'Souza; Abhijit Ray; Cheng Chang; Peter W Swaan
Journal:  Pharm Res       Date:  2005-04-07       Impact factor: 4.200

6.  Probiotic Pre-treatment Reduces Gliclazide Permeation (ex vivo) in Healthy Rats but Increases It in Diabetic Rats to the Level Seen in Untreated Healthy Rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Ranko Skrbic; Svetlana Golocorbin-Kon; Momir Mikov
Journal:  Arch Drug Inf       Date:  2008-07

7.  Development of a QSAR model for binding of tripeptides and tripeptidomimetics to the human intestinal di-/tripeptide transporter hPEPT1.

Authors:  Rikke Andersen; Flemming Steen Jørgensen; Lars Olsen; Jon Våbenø; Karina Thorn; Carsten Uhd Nielsen; Bente Steffansen
Journal:  Pharm Res       Date:  2006-02-26       Impact factor: 4.200

8.  Gliclazide reduces MKC intestinal transport in healthy but not diabetic rats.

Authors:  Hani Al-Salami; Grant Butt; Ian Tucker; Paul J Fawcett; Svetlana Golocorbin-Kon; Ivan Mikov; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Jan-Mar       Impact factor: 2.569

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.